Lean Meds vs Nova
A flat fifty-state rate against a two-state service that prices its fee inside the number.
Lean Meds
Editorial
$79/mo
Four terms published per molecule, with the month-to-month figure printed rather than implied. Compounded semaglutide stands at $79 a month; the advertised $69 is the twelve-month prepay tier. No membership is charged beside the medication, read in August 2026.
Pick it for: Buyers who want the lowest held rate and national coverage
Nova
Editorial
$139/mo
Two injection lines quoted as all-in figures that already contain a required care fee: $198 for semaglutide and $210 for tirzepatide, with shipping stated as included. A required fee named inside the price is a different proposition from one a buyer meets at checkout. The oral lines are quoted lower, at $156 and $174, but the oral semaglutide bills its first three months together at $269. Coverage is two states.
Pick it for: Buyers in Texas or Florida who want the service fee already counted
Our verdict
LeanMeds opens at $79 and holds; Nova opens higher, rises with the dose, and counts a mandatory care charge inside its injection figures. Coverage decides this for most readers.
What actually separates them
Lean Meds and Nova state different things about published price and where you can use it. Everything else they publish, they publish the same way.
Nova costs $60 more than Lean Meds — 76% more for the same molecule. Whether that buys anything is what the rest of this page is for.
Over twelve months that is about $948 at Lean Meds against $1,668 at Nova — a difference of $720.
| Lean Meds | Nova | |
|---|---|---|
| Published price | $79/mo | $139/mo |
| Where you can use it | 50 states | 2 states |
Before you choose either
Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against every published price we hold rather than against each other alone.
Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.